scholarly journals A Cost-Minimization Analysis of Paediatric Telehomecare Compared to Usual Care: the lower cost more than compensates a longer stay (Preprint)

10.2196/31628 ◽  
2021 ◽  
Author(s):  
Cristina Adroher Mas ◽  
Candela Esposito ◽  
Astrid Batlle Boada ◽  
Ricard Casadevall ◽  
Marta Millet ◽  
...  
Keyword(s):  
Usual Care ◽  
Lower Cost ◽  
Cost Minimization ◽  
Cost Minimization Analysis

A Cost-Minimization Analysis of Paediatric Telehomecare Compared to Usual Care: the lower cost more than compensates a longer stay (Preprint)

2021 ◽  
Author(s):  
Cristina Adroher Mas ◽  
Candela Esposito ◽  
Astrid Batlle Boada ◽  
Ricard Casadevall ◽  
Marta Millet ◽  
...  
Keyword(s):  
Usual Care ◽  
User Satisfaction ◽  
Cost Minimization ◽  
Adult Population ◽  
Hospital Costs ◽  
Control Group ◽  
Hospital Perspective ◽  
Cost Minimization Analysis ◽  
Hospitalization Costs ◽  
The Cost

BACKGROUND While home hospitalization has been a well-known and widespread practice for some time in the adult population, it has not been the same case in the paediatric setting. Simultaneously, telemedicine tools are a facilitator of the change in the healthcare model, which is increasingly focused on home care. In a pioneering way in Spain, the in-home hospitalization program of the Hospital Sant Joan de Déu in Barcelona allows the child to be in their home environment at the time they are being monitored and clinically followed by the professionals. In addition to being the preferred option for families, previous experience suggest that paediatric home hospitalization reduces costs, primarily thanks to savings on the structural cost of the stay. OBJECTIVE To compare the average cost of a discharge by telehomecare with the usual care and to analyse the main drivers of the differential costs of both care models. METHODS Cost-minimization analysis conducted under a hospital’s perspective, based on observational data and estimated retrospectively. A historical control group of similar patients in terms of clinical casuistry to children hospitalized at home was used for comparison. RESULTS A 24h stay at the hospital costs € 503.68, while the in-home hospitalization costs € 264.66 per day, representing a saving of almost half (48%) of the cost compared to usual care. The main savings drivers were the personnel costs (35.5% of the total), intermediate non-care costs (33.17%), and structural costs (19.04%). Home hospitalization involves a total stay 27.61% longer, but at a daily cost of almost half, represents a € 155 (9.01%) per 24h stay saving. CONCLUSIONS The cost analysis conducted under a hospital perspective shows that paediatric telehomecare is 9% cheaper compared to regular hospital care. These results motivate the most widespread implementation of the service from the point of view of economic efficiency, adding to previous experiences that suggest that it is also preferable from the perspective of user satisfaction.

Cost-minimization analysis of drugs used in the treatment of Asthma and COPD diseases in India

2020 ◽  
Vol 15 ◽  
Author(s):  
Billu Payal ◽  
Anoop Kumar ◽  
Harsh Saxena
Keyword(s):  
Generic Drugs ◽  
Cost Minimization ◽  
Cost Savings ◽  
Chronic Obstructive ◽  
Pulmonary Medicine ◽  
Potential Cost ◽  
Maximum Cost ◽  
Cost Minimization Analysis ◽  
Cost Variation ◽  
The Cost

Background: Asthma and Chronic Obstructive Pulmonary Diseases (COPD) are well known respiratory diseases affecting millions of peoples in India. In the market, various branded generics, as well as generic drugs, are available for their treatment and how much cost will be saved by utilizing generic medicine is still unclear among physicians. Thus, the main aim of the current investigation was to perform cost-minimization analysis of generic versus branded generic (high and low expensive) drugs and branded generic (high expensive) versus branded generic (least expensive) used in the Department of Pulmonary Medicine of Era Medical University, Lucknow for the treatment of asthma and COPD. Methodology: The current index of medical stores (CIMS) was referred for the cost of branded drugs whereas the cost of generic drugs was taken from Jan Aushadi scheme of India 2016. The percentage of cost variation particularly to Asthma and COPD regimens on substituting available generic drugs was calculated using standard formula and costs were presented in Indian Rupees (as of 2019). Results: The maximum cost variation was found between the respules budesonide high expensive branded generic versus least expensive branded generic drugs and generic versus high expensive branded generic. In combination, the maximum cost variation was observed in the montelukast and levocetirizine combination. Conclusion: In conclusion, this study inferred that substituting generic antiasthmatics and COPD drugs can bring potential cost savings in patients.

scholarly journals Cost Minimization Analysis Of U100 Insulin And U40 Insulin In Egyptian Diabetic Patients

2014 ◽  
Vol 17 (7) ◽  
pp. A745
Author(s):  
Metry ABS ◽  
ElSisi GHAE ◽  
Abou Rawash ◽  
A Abo Taleb
Keyword(s):  
Cost Minimization ◽  
Diabetic Patients ◽  
Cost Minimization Analysis

Pharmacoeconomic features of the use of drugs used in the treatment of allergic rhinitis

2021 ◽  
pp. 9-16
Author(s):  
Afanasyeva T.G. ◽  
Lavrova N.N. ◽  
Tumentseva V.R.
Keyword(s):  
Quality Of Life ◽  
Allergic Rhinitis ◽  
Nasal Mucosa ◽  
Generic Drugs ◽  
Cost Minimization ◽  
Nasal Congestion ◽  
World Health ◽  
Cost Minimization Analysis ◽  
Wide Range

Rhinitis is an inflammation of the nasal mucosa; today, according to the World Health Organization, the prevalence of the disease is 40% of the world's population. Allergic rhinitis is the most common type of chronic rhinitis, affecting 10–20% of the world's population, and the severity of the disease is associated with a significant deterioration in the quality of life, sleep and performance. Allergic rhinitis is an inflammatory disease of the nasal mucosa caused by exposure to an allergen, causing IgE-mediated inflammation. Clinically, the disease is characterized by the following main symptoms: rhinorrhea, sneezing, itching and nasal congestion. Despite the general symptoms of allergic rhinitis, its impact on the quality of life of patients and the significant cost of treatment, including pharmacotherapy, many patients do not adhere to drug treatment regimens due to their insufficient effectiveness in eliminating the emerging symptoms. Pharmacoeconomic research identifies, measures and compares the costs and effects of drug use. This framework includes research methods related to cost minimization, cost-effectiveness, decision analysis, cost of illness, and patient quality of life. This article will consider one of the four main methods for assessing pharmacoeconomics - cost minimization analysis. A cost-minimization analysis is a pharmacoeconomic assessment by comparing the costs of two or more drug alternatives regardless of outcome. Since the pharmaceutical market is represented by a wide range of original, reference and generic drugs for the treatment of allergic rhinitis, an important aspect of our research is the selection of effective and economically acceptable therapy for outpatients.

Sign in / Sign up

Export Citation Format

Share Document